State Generic Substitution Laws Can Lower Drug Outlays Under Medicaid
- 1 July 2010
- journal article
- research article
- Published by Health Affairs (Project Hope) in Health Affairs
- Vol. 29 (7), 1383-1390
- https://doi.org/10.1377/hlthaff.2009.0424
Abstract
To stem the rising costs of medications provided to patients enrolled in Medicaid, states have implemented varying policies about generic substitution. These policies differ in the extent to which pharmacists or patients can influence which medications they choose. Using national Medicaid data, we evaluated the relationship between different generic substitution policies and the use of generic simvastatin, a cholesterol-lowering drug, after the patent for the brand-name equivalent, Zocor, expired. States that implemented policies requiring patients’ consent prior to generic substitution experienced rates of substitution that were 25 percent lower than those of states that did not require patient consent. By eliminating patient consent requirements, state Medicaid programs could expect to save more than $100 million in coverage for three top-selling medications that are nearing patent expiration. Although these consent requirements are probably intended to increase patient autonomy, policy makers should consider the sizable opportunity costs.Keywords
This publication has 13 references indexed in Scilit:
- Patients’ Perceptions Of Generic MedicationsHealth Affairs, 2009
- Clinical Equivalence of Generic and Brand-Name Drugs Used in Cardiovascular DiseaseJAMA, 2008
- Beliefs about generic drugs among elderly adults in hospital-based primary care practicesPatient Education and Counseling, 2008
- Prescription Drug Spending Trends In The United States: Looking Beyond The Turning PointHealth Affairs, 2008
- Patient, Physician, Pharmacy, and Pharmacy Benefit Design Factors Related to Generic Medication UseJournal of General Internal Medicine, 2007
- Impact of a generic substitution reform on patients’ and society's expenditure for pharmaceuticalsHealth Policy, 2007
- Authorized GenericsNature Reviews Drug Discovery, 2005
- Medicaid Prior-Authorization Programs and the Use of Cyclooxygenase-2 InhibitorsNew England Journal of Medicine, 2004
- The Effects of Differences in State Drug Product Selection Laws on Pharmacists?? Substitution BehaviorMedical Care, 1987
- Evaluation of Economic Effects of Drug Product Selection LegislationMedical Care, 1979